Chugai Transfers Manufacturing of Leukemia Drug to Fuji Pharma
By

By
Chugai Pharmaceutical has agreed to transfer the rights to manufacture and market the anti-leukemia drug, Vesanoid (tretinoin), in Japan to Fuji Pharma, effective on November 1, 2016. Vesanoid is an…

Allergan Acquires Gene-Therapy Company
By

By
Allergan has acquired all assets of RetroSense Therapeutics, an Ann Arbor, Michigan-based clinical-stage biotechnology company focused on gene therapy, in an all-cash transaction. Allergan has paid RetroSense a $60-million upfront…

EC OKs New Use for BMS’ Arthritis Drug
By

By
Bristol-Myers Squibb has received approval from the European Commission for a new use for it rheumatoid arthritis (RA) drug, Orencia (abatacept) intravenous infusion and subcutaneous injection. The drug is now…

Merck & Co. Discontinues Development of Osteoporosis Drug
By

By
Merck & Co. has decided to discontinue the development of odanacatib, its investigational cathepsin-K inhibitor for osteoporosis, and will not seek regulatory approval for its use. The company has decided…

Amgen, Servier Extend Pact for Heart Failure Drug
By

By
Amgen and Servier, a French pharmaceutical company, have advanced their cardiovascular drug collaboration, with Servier exercising its option to commercialize omecamtiv mecarbil in chronic heart failure in Europe as well…

Allergan Settles Patent-Infringement Litigation For Alzheimer’s Drug
By

By
Allergan and its subsidiaries, Forest Laboratories, Forest Laboratories Holdings, and Allergan USA, along with Adamas Pharmaceuticals, have settled patent-infringement litigation with Amneal Pharmaceuticals and Amneal Pharmaceuticals of New York for…

Galenica Completes $1.53 Billion Acquisition of Relypsa
By

By
Galenica Group, a Bern, Switzerland-based specialty pharmaceutical company, has completed its previously announced acquisition of the Redwood City, California-based biopharmaceutical company, Relypsa. Galenica's Vifor Pharma Business unit will be combined…

FDA Fast Tracks Biogen’s Alzheimer’s Drug
By

By
Biogen was granted fast track designation by the US Food and Drug Administration for aducanumab, its investigational treatment for early Alzheimer's disease (AD). Aducanumab is currently being evaluated in two…

FDA OKs Pediatric Use for Amgen’s Leukemia Drug
By

By
Amgen has received approval from the US Food and Drug Administration (FDA) for a supplemental biologics license application for Blincyto (blinatumomab) to include new data for treating pediatric patients with…

Amgen Gets Rights To BI’s BiTE Immuno-Oncology Drug
By

By
Amgen has acquired global development and commercial rights to Boehringer Ingelheim's (BI) bispecific T-cell engager (BiTE) immuno-oncology drug, BI 836909 (AMG 420), which is under investigation for treating multiple myeloma.…